A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: McPherson, Stuart, Wilkinson, Nina, Tiniakos, Dina, Wilkinson, Jennifer, Burt, Alastair D., McColl, Elaine, Stocken, Deborah D., Steen, Nick, Barnes, Jane, Goudie, Nicola, Stewart, Stephen, Bury, Yvonne, Mann, Derek, Anstee, Quentin M., Day, Christopher P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395178/
https://www.ncbi.nlm.nih.gov/pubmed/28419124
http://dx.doi.org/10.1371/journal.pone.0175717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395178/
https://www.ncbi.nlm.nih.gov/pubmed/28419124
http://dx.doi.org/10.1371/journal.pone.0175717

Ejemplares similares